Detalles de la búsqueda
1.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35939812
2.
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Liver Int
; 40(5): 1042-1051, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31765046
3.
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
J Viral Hepat
; 26(3): 329-336, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412325
4.
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
J Gastroenterol Hepatol
; 34(9): 1597-1603, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779220
5.
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
J Gastroenterol Hepatol
; 34(1): 12-21, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30311701
6.
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.
Future Oncol
; 15(9): 943-952, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30777447
7.
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Gastroenterology
; 152(6): 1372-1382.e2, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28193518
8.
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Am J Gastroenterol
; 113(6): 863-871, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695828
9.
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Hepatology
; 65(2): 439-450, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770561
10.
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Hepatology
; 66(3): 736-745, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28256747
11.
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Liver Int
; 38(9): 1583-1591, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29461687
12.
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.
Hepatol Res
; 47(12): 1340-1345, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28334495
13.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467560
14.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467591
15.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24727022
16.
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Clin Infect Dis
; 59(12): 1657-65, 2014 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25266289
17.
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
Clin Gastroenterol Hepatol
; 12(6): 1029-37.e5, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24120953
18.
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
J Hepatol
; 59(1): 11-7, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23439259
19.
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Hepatology
; 56(3): 884-93, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22473713
20.
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.
J Infect
; 87(5): 392-402, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37690669